Home » Stocks » LQDA

Liquidia Technologies, Inc. (LQDA)

Stock Price: $2.72 USD -0.02 (-0.73%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $2.74 +0.02 (0.74%) May 14, 7:29 PM
Market Cap 141.37M
Revenue (ttm) 3.82M
Net Income (ttm) -54.15M
Shares Out 51.97M
EPS (ttm) -1.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $2.72
Previous Close $2.74
Change ($) -0.02
Change (%) -0.73%
Day's Open 2.79
Day's Range 2.67 - 2.84
Day's Volume 310,927
52-Week Range 2.34 - 3.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -5.00% and 260.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the st...

3 days ago - Zacks Investment Research

- Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery - Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder - Improved financial position w...

3 days ago - GlobeNewsWire

MORRISVILLE, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on May 7, 2021, it resubmitted its New Drug Application (NDA) for LIQ861 for the treatment of...

6 days ago - GlobeNewsWire

MORRISVILLE, N.C., May 06, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2021 financial results on Thursday, May 13, 2021. The compan...

1 week ago - GlobeNewsWire

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: ALYA, CPRT, CRDF, NBRV
2 weeks ago - Zacks Investment Research

RESEARCH TRIANGLE PARK, N.C., April 13, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has entered into a common stock purchase agreement with certain institutional...

1 month ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., March 30, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Treprostinil Injection, a generic form of Remoduli...

1 month ago - GlobeNewsWire

-  Integrated RareGen (now known as Liquidia PAH) to establish commercial presence in PAH -  Clarified path towards submitting response to CRL for LIQ861 in mid-2021 -  Reducing net annual spending more...

1 month ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., March 09, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that 2020 financial results will be reported on Tuesday, March 23, 2021. The company ...

2 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the closing of a debt facility on February 26, 2021, with Silicon Valley Bank, which ...

2 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $LQDA #LQDA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation.

4 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $LQDA #LQDA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Liquidia Corporation.

4 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Liquidia Corporation (NASDAQ: LQDA) r...

4 months ago - Business Wire

NEW YORK, Dec. 20, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA).   Such investors are advise...

4 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Damian deGoa has been appointed as Chief Executive Officer (CEO) and a director of the...

5 months ago - GlobeNewsWire

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA).   Such investors are advise...

5 months ago - GlobeNewsWire

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation (“Liquidia” or the “Company”) (NASDAQ: LQDA). Such investors are advised ...

5 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Chief Financial Officer (CFO), effective immediately...

5 months ago - GlobeNewsWire

The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form

5 months ago - Zacks Investment Research

NEW YORK, Nov. 25, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to c...

5 months ago - PRNewsWire

CRL does not cite need for additional clinical studies

5 months ago - GlobeNewsWire

Merger Reinforc es Company's Commitment to Patients with PAH

5 months ago - GlobeNewsWire

Stockholders Approve RareGen Acquisition

6 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializati...

6 months ago - GlobeNewsWire

Liquidia Technologies, Inc. (LQDA) CEO Neal Fowler on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

- Raised $75 M illion through Underwritten Public Offering - Bolstered and Defended LIQ861 Patent Position - Advanced Efforts in Support of the RareGen, LLC Merger and Integration - Company to Host Webc...

6 months ago - GlobeNewsWire

Company Determines Unsolicited Offer does not Constitute Superior Proposal

6 months ago - GlobeNewsWire

Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET

6 months ago - GlobeNewsWire

Company to Host Webcast and Conference Call November 9, 2020 at 8:00p.m. ET Company to Host Webcast and Conference Call November 9, 2020 at 8:00p.m. ET

6 months ago - GlobeNewsWire

Lead candidate LIQ861 has shown an equivalent safety profile to UTHR's Tyvaso, and is also a bit easier to use.

6 months ago - Seeking Alpha

RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializati...

6 months ago - GlobeNewsWire

PTAB Institutes Inter Partes Review Proceeding Against United Therapeutics’ ‘901 Patent and Denies Institution on ‘066 Patent for Tyvaso® PTAB Institutes Inter Partes Review Proceeding Against United Th...

7 months ago - GlobeNewsWire

Dr. O’Brien Joins Liquidia with 25 Years of Medical Practice Experience in Pulmonary Critical Care Dr. O’Brien Joins Liquidia with 25 Years of Medical Practice Experience in Pulmonary Critical Care

7 months ago - GlobeNewsWire

Special Meeting of Liquidia Technologies, Inc. Stockholders Scheduled for October 21, 2020 Special Meeting of Liquidia Technologies, Inc. Stockholders Scheduled for October 21, 2020

7 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializa...

8 months ago - GlobeNewsWire

Steven Bariahtaris Appointed Interim Chief Financial Officer Steven Bariahtaris Appointed Interim Chief Financial Officer

8 months ago - GlobeNewsWire

Liquidia Technologies, Inc. (LQDA) CEO Neal Fowler on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializa...

9 months ago - GlobeNewsWire

New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension (PAH) patients demonstrate positive trends in exploratory endpoints, including quality of life (QoL) New dat...

9 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializat...

9 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., July 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializa...

9 months ago - GlobeNewsWire

When Wall Street ignores micro-cap stocks, it creates deep value opportunities, if a company is able to turn things around against fortune.

Other stocks mentioned: ARLO, ITRN, RADA, SWIR, VERI, XBIT
9 months ago - InvestorPlace

Liquidia Technologies Inc. (NASDAQ: LQDA) has seen its share of news after an acquisition and a recent stock sale.

10 months ago - 24/7 Wall Street

RESEARCH TRIANGLE PARK, N.C., July 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializa...

10 months ago - GlobeNewsWire

Today has brought good news. Consumer confidence is better than expected and unemployment has decreased.

Other stocks mentioned: BCRX, FLNT, GRUB, MNKD
10 months ago - Forbes

RESEARCH TRIANGLE PARK, N.C., June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializa...

10 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializa...

10 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializa...

10 months ago - GlobeNewsWire

If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify several Top Shor...

Other stocks mentioned: AGLE, DVAX, PHAS, SEEL
10 months ago - Forbes

Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several Top Shorts...

Other stocks mentioned: BLNK, NAVB, SVRA
11 months ago - Forbes

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered... [Read more...]

Industry
Biotechnology
IPO Date
Jul 26, 2018
Stock Exchange
NASDAQ
Ticker Symbol
LQDA
Full Company Profile

Financial Performance

In 2020, LQDA's revenue was $739,628, a decrease of -90.84% compared to the previous year's $8.07 million. Losses were -$59.76 million, 25.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for LQDA stock is "Buy." The 12-month stock price forecast is 4.25, which is an increase of 56.25% from the latest price.

Price Target
$4.25
(56.25% upside)
Analyst Consensus: Buy